Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
January 1, 2026Sunhwan'giOpen Access

Temporal Trend of Cardiovascular Disease Burden Among Cancer Patients Between 2005 and 2022: Nationwide Population-Based Cohort Study in South Korea

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Comprehensive data on the changing landscape of cardiovascular disease burden in cancer patients remained limited.

Population

1,322,502 adults aged ≥18 newly diagnosed with cancer in Korea

Comparison

Temporal trends from 2005 to 2022

Design

Nationwide population-based cohort study

Key result

Between 2005 and 2022, 1-year cardiovascular disease incidence in cancer patients initially decreased but later increased, driven by a 136% rise in heart failure incidence.

Authors

ICIksung ChoSLSeonhwa LeeJCJaehyeong Cho

Discussion

Loading...

Member takes

Overview

May signal need for intensified HF monitoring in cancer survivors; hypothesis-generating for targeted cardio-oncology prevention strategies.

Study Design

Type

Cohort (n=1,322,502)

Structured PICO

P
Population
1,322,502 adults aged 18 and older newly diagnosed with cancer in South Korea between 2005 and 2022, followed for up to 5 years to assess cardiovascular disease incidence and mortality trends.
O
Outcome
Temporal trends in cardiovascular disease (CVD) incidence (including ischemic heart disease, heart failure, and stroke) and cause-specific mortality trends (focusing on cancer and CVD-related deaths) at 1-, 3-, and 5-year follow-ups.hard clinical

While cancer-specific mortality has improved, cardiovascular mortality in cancer patients is an increasing concern, driven largely by a rising burden of heart failure.

Limitations

  • Lacks detailed information on cancer stages, specific treatments, and lifestyle factors
  • Reliance solely on ICD-10 codes may fail to capture real-world diagnostic complexity fully
  • Inability to apply a more stringent operational definition of heart failure (e.g., LVEF, BNP levels)
  • Competing risk of non-CVD death was not explicitly accounted for
  • Changes in diagnostic practices and insurance coverage may have influenced trends
  • Newer agents such as immune checkpoint inhibitors were not fully captured
  • 5-year follow-up limits understanding of longer-term cardiovascular outcomes
  • Observational study design prevents definitive causal inference

Cite This Study

Cho et al. (2026) conducted a cohort in Cancer (n=1,322,502). Time period (2005-2022) was evaluated on Temporal trends in cardiovascular disease incidence and cause-specific mortality. Between 2005 and 2022, 1-year cardiovascular disease incidence in cancer patients initially decreased but later increased, driven by a 136% rise in heart failure incidence.

synapsesocial.com/papers/6a9884dfbae5775bb63df64bhttps://doi.org/10.4070/kcj.2025.0171
View Full Paper
Ask AI
Bookmark
Share